Pfizer/AstraZeneca and the Public Interest: Do U.K. Foreign Takeover Proposals Prescribe an Effective Remedy?

This article is part of a Chronicle. See more from this Chronicle

David Reader, Oct 15, 2014

When U.S. pharmaceutical giant Pfizer sought to acquire its U.K.-listed counterpart AstraZeneca earlier this year, much discussion centered around the possible adverse impact that the merger could have on the U.K.’s science base, particularly in light of Pfizer’s questionable track record for asset-stripping and cutting investment in Research and Development (“R&D”). Although the proposed £69 billion (U.S. $117 billion) takeover ultimately crumbled, the prospect of Pfizer returning with …

ACCESS TO THIS ARTICLE IS RESTRICTED TO SUBSCRIBERS

Please sign in or join us
to access premium content!